Amgen's earnings call highlighted strong performance across various product lines, especially Repatha, EVENITY, and BLINCYTO.  Management expressed confidence in the company's pipeline, particularly with promising data from early-stage molecules like MariTide and Tarlatamab.  Positive guidance and robust growth projections suggest minimal short-term risk.
[1]
